Haruhide Kimura Selected Research

Muscarinic M1 Receptor

11/2021	Therapeutic potential of TAK-071, a muscarinic M1 receptor positive allosteric modulator with low cooperativity, for the treatment of cognitive deficits and negative symptoms associated with schizophrenia.
1/2019	TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys.
1/2019	TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects.
1/2018	An Approach to Discovering Novel Muscarinic M1 Receptor Positive Allosteric Modulators with Potent Cognitive Improvement and Minimized Gastrointestinal Dysfunction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haruhide Kimura Research Topics

Disease

15	Schizophrenia (Dementia Praecox) 11/2021 - 11/2014
5	Neurodevelopmental Disorders 09/2022 - 01/2019
5	Diarrhea 01/2020 - 01/2011
4	Cognitive Dysfunction 11/2021 - 01/2018
4	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 01/2018
3	Memory Disorders (Memory Loss) 09/2022 - 01/2020
3	Dementia (Dementias) 01/2020 - 01/2019
3	Huntington Disease (Huntington's Disease) 01/2017 - 01/2015
2	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2019
2	Treatment-Resistant Depressive Disorder 12/2021 - 01/2019
2	Major Depressive Disorder (Major Depressive Disorders) 12/2021 - 01/2019
2	Stroke (Strokes) 08/2021 - 01/2021
1	Rodent Diseases 01/2022
1	Intellectual Disability (Idiocy) 03/2021
1	Kabuki syndrome 03/2021
1	Autistic Disorder (Autism) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Parkinson Disease (Parkinson's Disease) 01/2020
1	Narcolepsy 12/2019
1	Disorders of Excessive Somnolence (Hypersomnia) 12/2019
1	Neurobehavioral Manifestations 01/2019
1	Psychotic Disorders (Schizoaffective Disorder) 01/2018
1	Basal Ganglia Diseases (Basal Ganglia Disease) 01/2018
1	Hyperkinesis 01/2018
1	Nervous System Diseases (Neurological Disorders) 01/2018
1	Chorea (Rheumatic Chorea) 01/2018
1	Body Weight (Weight, Body) 01/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2016
1	Central Nervous System Diseases (CNS Diseases) 01/2015
1	Shock 01/2013
1	Sepsis (Septicemia) 01/2013
1	Weight Gain 01/2011
1	Colitis 01/2011
1	Hemorrhage 01/2011
1	Osteoarthritis 06/2009

Drug/Important Bio-Agent (IBA)

9	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 08/2021 - 01/2015
6	Pharmaceutical PreparationsIBA 12/2021 - 01/2013
6	1- (2- fluoro- 4- (1H- pyrazol- 1- yl)phenyl)- 5- methoxy- 3- (1- phenyl- 1H- pyrazol- 5- yl)pyridazin- 4(1H)- oneIBA 01/2021 - 03/2015
5	Antipsychotic Agents (Antipsychotics)IBA 11/2021 - 03/2016
5	Cholinergic Agents (Cholinergics)IBA 11/2021 - 01/2019
4	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 09/2022 - 03/2016
4	EnzymesIBA 01/2022 - 01/2019
4	Lysine (L-Lysine)FDA Link 01/2022 - 01/2019
4	Muscarinic M1 ReceptorIBA 11/2021 - 01/2018
3	TAK-418IBA 09/2022 - 01/2021
3	TAK-071IBA 11/2021 - 01/2019
3	Histones (Histone)IBA 03/2021 - 01/2019
3	Scopolamine (Hyoscine)FDA Link 01/2020 - 01/2018
3	Guanosine Monophosphate (5' Guanylic Acid)IBA 01/2018 - 11/2014
3	Adenosine Monophosphate (AMP)IBA 01/2018 - 11/2014
2	Ketamine FDA LinkGeneric 12/2021 - 01/2019
2	Antidepressive Agents (Antidepressants)IBA 12/2021 - 01/2019
2	AcidsIBA 01/2019 - 01/2018
2	TAK-137IBA 01/2019 - 01/2019
2	Dihydrotachysterol (AT 10)IBA 01/2019 - 01/2018
2	AMPA Receptors (AMPA Receptor)IBA 01/2019 - 01/2018
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2018 - 01/2017
2	Phencyclidine (Angel Dust)IBA 03/2016 - 11/2014
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Amyloid (Amyloid Fibrils)IBA 01/2022
1	Poly I-CIBA 11/2021
1	MethyltransferasesIBA 03/2021
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2021
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2020
1	Donepezil (Aricept)FDA LinkGeneric 01/2020
1	SynucleinsIBA 01/2020
1	TAK-925IBA 12/2019
1	OrexinsIBA 12/2019
1	Glutamic Acid (Glutamate)FDA Link 01/2019
1	Ionotropic Glutamate ReceptorsIBA 01/2019
1	Tranylcypromine (Parnate)FDA LinkGeneric 01/2019
1	Flavin-Adenine Dinucleotide (FAD)IBA 01/2019
1	xanomelineIBA 01/2019
1	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2019
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2019
1	Coenzymes (Enzyme Cofactors)IBA 01/2019
1	Dopamine (Intropin)FDA LinkGeneric 01/2018
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2018
1	Carboxylic AcidsIBA 01/2018
1	3',5'-Cyclic-AMP Phosphodiesterases (3',5' Cyclic Nucleotide Phosphodiesterase)IBA 01/2018
1	QuinolonesIBA 01/2018
1	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 01/2018
1	Serine (L-Serine)FDA Link 10/2016
1	IminesIBA 03/2016
1	Dizocilpine Maleate (Dizocilpine)IBA 03/2016
1	LipopolysaccharidesIBA 01/2013
1	GalactosamineIBA 01/2013
1	Dextran SulfateIBA 01/2011
1	Sulfonic AcidsIBA 01/2011
1	Peroxidase (Myeloperoxidase)IBA 01/2011
1	sym-trinitrobenzeneIBA 01/2011
1	CollagenIBA 06/2009
1	Proteoglycans (Proteoglycan)IBA 06/2009
1	Interleukin-1beta (Interleukin 1 beta)IBA 06/2009

Therapy/Procedure

2	Oral Administration 09/2022 - 11/2014
2	Therapeutics 11/2021 - 01/2019